Help Us Cure Alzheimer's Disease
Our lab Principal Investigator and several members have been studying the underlying causes of AD for over two decades and we have shown that drug discovery largely following a "Pharma" model but in an academic setting can lead to clinical candidates. In fact, we believe the academic setting provides greater freedom, creativity and ability to "stay the course" for longer than in a pharmaceutical company driven by profit potential. But, as we are not a company, we need support to meet the challenge of translating basic research into a safe and effective new pharmaceutical. The time from initial discovery to efficacy testing in the clinic can easily span more than 10 years, and many compounds fall out of development during this time. This may not necessarily be because a potential new therapeutic has been found to be ineffective, but for the lack of funds to support the work. If you would like to help us take a promising compound from lab bench to bedside, please contact us or follow the links on this site to make a donation.
For more information, contact:
It is projected that the people in the U.S. with Alzheimer's will close to triple by 2050, while the total cost of treatment will increase by 6-fold. However, even with such a drastic increase in cost, the amount of funding provided for Alzheimer's research will increase just a comparatively negligible amount. It's more important now than ever to fund research and drug development to cure Alzheimer's as the number of people affected by it and the cost of treating it increase.
Sources: Alzheimer's Study Group, A National Alzheimer's Strategic Plan: The Report of the Alzheimer's Study Group (March 2000); Alzheimer's Association, 2009 Alzheimer's Disease Facts and Figures (March 2009); National Institute of Health Office of the Budget.